More pressure for generics in Japan

7 June 2009

The Fiscal System Council of Japan's Ministry of Finance has recommended the government to promote the use of generic medicines to  improve efficiency in drug benefits so as to make the current National  Health Insurance system sustainable within the constraints of the 2010  fiscal year social security budget.

The council stressed the need to tackle ways of ensuring stable  financial resources, improving efficiency of drug benefits, including  the promotion of copy-drug use, and computerization of medical bills, as  well as considering new taxation and insurance premiums as financial  resources for the health insurance system.

The FSC also recommends the government to seek the budget ceiling when  discussing the FY 2010 revision of medical fees and NHI drug prices from  the viewpoint of the trends in salaries among the private sectors and  consumer prices, reports the Marketletter's correspondent.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight